MENU
BBC
ETF ticker: NYSE ARCA
PRICE
CHANGE
NET ASSETS

BBC stock forecast, quote, news & analysis

The investment seeks investment results that correspond, before fees and expenses, to the price and yield performance of the LifeSci Biotechnology Clinical Trials Index... Show more

Category: #Health
Interact to see
Advertisement
A.I.Advisor
published price charts
BBC
Daily Signal:
Gain/Loss:
A.I.Advisor
a Summary for BBC with price predictions
Oct 22, 2026

BBC's MACD Histogram crosses above signal line

The Moving Average Convergence Divergence (MACD) for BBC turned positive on October 21, 2026. Looking at past instances where BBC's MACD turned positive, the stock continued to rise in 45 of 48 cases over the following month. The odds of a continued upward trend are 90%.

Price Prediction Chart

Technical Analysis (Indicators)

Bullish Trend Analysis

The RSI Oscillator points to a transition from a downward trend to an upward trend -- in cases where BBC's RSI Oscillator exited the oversold zone, 25 of 32 resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 78%.

The Stochastic Oscillator suggests the stock price trend may be in a reversal from a downward trend to an upward trend. 55 of 65 cases where BBC's Stochastic Oscillator exited the oversold zone resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 85%.

Following a +8.92% 3-day Advance, the price is estimated to grow further. Considering data from situations where BBC advanced for three days, in 276 of 305 cases, the price rose further within the following month. The odds of a continued upward trend are 90%.

BBC may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.

Bearish Trend Analysis

Following a 3-day decline, the stock is projected to fall further. Considering past instances where BBC declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 90%.

The Aroon Indicator for BBC entered a downward trend on October 22, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.

A.I.Advisor
published Highlights

Notable companies

The most notable companies in this group are Nektar Therapeutics (NASDAQ:NKTR).

Industry description

The investment seeks investment results that correspond, before fees and expenses, to the price and yield performance of the LifeSci Biotechnology Clinical Trials Index. Under normal market conditions, the fund will invest not less than 80% of its assets in component securities of the index. The index seeks to track the performance of the common stock of U.S. exchange-listed biotechnology companies with a primary product offering ("lead drug") that is typically in a Phase 1, Phase 2 or Phase 3 clinical trial stage of development, but prior to receiving marketing approval.

Market Cap

The average market capitalization across the Virtus Biotech Clinical Trials ETF (BBC) ETF is 2.43B. The market cap for tickers in the group ranges from 36.91M to 40.23B. RVMD holds the highest valuation in this group at 40.23B. The lowest valued company is EYPT at 36.91M.

High and low price notable news

The average weekly price growth across all stocks in the Virtus Biotech Clinical Trials ETF (BBC) ETF was 2%. For the same ETF, the average monthly price growth was -15%, and the average quarterly price growth was -8%. IRON experienced the highest price growth at 32%, while EYPT experienced the biggest fall at -86%.

Volume

The average weekly volume growth across all stocks in the Virtus Biotech Clinical Trials ETF (BBC) ETF was -4%. For the same stocks of the ETF, the average monthly volume growth was -12% and the average quarterly volume growth was -20%

Fundamental Analysis Ratings

The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows

Valuation Rating: 42
P/E Growth Rating: 38
Price Growth Rating: 62
SMR Rating: 94
Profit Risk Rating: 89
Seasonality Score: 9 (-100 ... +100)